AUG 8·SEC EDGARLow
Redmile Group, LLC purchased $6.8M of ATTO (indirect holdings)
Redmile Group, LLC purchased 400,000 indirectly-held shares of Attovia Therapeutics, Inc. (ATTO) at $17.00 ($6.80M total) on 2026-08-06.
Stock
$ATTO
Attovia Therapeutics, Inc.
Price · $ATTOvia TradingView
AI sentiment · 7d5 articles
- Bullish
- 5
- Neutral
- 0
- Bearish
- 0
Top stories · $ATTOMore →
AUG 8·SEC EDGAR
Redmile Group, LLC purchased $3.4M of ATTO
Redmile Group, LLC purchased 200,000 shares of Attovia Therapeutics, Inc. (ATTO) at $17.00 ($3.40M total) on 2026-08-06.
AUG 7·SEC EDGAR
Sanofi purchased $5.1M of ATTO (indirect holdings)
Sanofi purchased 300,000 indirectly-held shares of Attovia Therapeutics, Inc. (ATTO) at $17.00 ($5.10M total) on 2026-08-06.
ATTO sentiment & insider activity
Over the past 7 days, alphai's AI scored 5 news stories mentioning ATTO (Attovia Therapeutics, Inc.). Coverage has skewed bullish: 5 bullish, 0 neutral, and 0 bearish.
Recent ATTO coverage spans ipo, insider activity and market movers.
In the last 30 days, ATTO insiders filed 4 SEC Form 4 transactions — 4 purchases ($25.3M) and no sales. The most active reporter was Redmile Group, LLC with 2 filings.
What's driving ATTO
The filing signals incremental insider-style accumulation by a large holder, but it is not a company fundamental update.
The filing discloses a sizable open-market purchase by a 10% owner, which can be read as incremental bullish conviction but is not a fundamental update like guidance or trial data.
The filing signals Sanofi’s continued accumulation via a 10% owner role, but it is not a fundamental catalyst like guidance, trial data, or a deal.
The amended S-1 upsizes proceeds and ties funding to near-term Phase II initiation, which can improve financing runway and de-risk development timing.
The filing signals insider/large-holder accumulation, but it is not a fundamental catalyst like earnings, guidance, or a deal.
alphai scores every news story that mentions ATTO with an AI model for sentiment and relevance, and aggregates insider trades from Attovia Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $ATTO
Score
Redmile Group, LLC purchased $6.8M of ATTO (indirect holdings)
Redmile Group, LLC purchased 400,000 indirectly-held shares of Attovia Therapeutics, Inc. (ATTO) at $17.00 ($6.80M total) on 2026-08-06.
2 min readRedmile Group, LLC purchased $3.4M of ATTO
Redmile Group, LLC purchased 200,000 shares of Attovia Therapeutics, Inc. (ATTO) at $17.00 ($3.40M total) on 2026-08-06.
2 min readSanofi purchased $5.1M of ATTO (indirect holdings)
Sanofi purchased 300,000 indirectly-held shares of Attovia Therapeutics, Inc. (ATTO) at $17.00 ($5.10M total) on 2026-08-06.
2 min read
Attovia raises $265m in upsized IPO for trials
Attovia filed an amended S-1 for an upsized IPO raising about $265.1 million in net proceeds, up from roughly $182.4 million earlier. Funds will support two Phase II trials starting in H1 2027 for ATTO-1310, an engineered biologic targeting IL-31 for chronic pruritic diseases. The filing cites Phase Ib results and prior funding rounds.
4 min readFrazier Life Sciences XI, L.P. purchased $10.0M of ATTO
Frazier Life Sciences XI, L.P. purchased 588,235 shares of Attovia Therapeutics, Inc. (ATTO) at $17.00 ($10.00M total) on 2026-08-06.
2 min read
Top Biotech Gainers: ATTO Debuts, AMWL Cuts Loss, PRGO Returns To The Black, URGN Hits New High
Biotech stocks rose as several companies reported updates. Attovia Therapeutics (ATTO) jumped over 28% after its Nasdaq debut at $17 and a close at $21.90. American Well (AMWL) gained about 25% after Q2 loss narrowed to $9.6M, though revenue fell to $52.0M. Perrigo (PRGO) swung to Q2 net income of $74.5M. UroGen (URGN) rose after Q2 revenue increased to $72.5M.
3 min readAttovia Therapeutics shares jump 24% in trading debut after IPO
Attovia Therapeutics Inc. (NASDAQ:ATTO) shares rose 24% in their trading debut after the clinical-stage biopharma raised $289 million in its IPO. Shares opened at $21 versus a $17 IPO price, valuing the company near $904 million. The IPO sold 17 million shares, with an option for up to 2.55 million more.
2 min readAttovia Therapeutics prices IPO at $17 per share on Nasdaq
Attovia Therapeutics (Nasdaq: ATTO) priced its IPO at $17.00 per share, selling 17.0 million shares for expected gross proceeds of about $289.0 million, with a 30-day option for up to 2.55 million more shares. The stock is set to start trading Aug. 5, 2026, under ATTO. Joint bookrunners include Morgan Stanley, Leerink, Citigroup, and RBC.
3 min readGoldman Sachs-backed Attovia eyes $731.5 million valuation in upsized US IPO
Attovia Therapeutics, a biopharma company, said it is targeting a $731.5 million valuation in an upsized US IPO. It plans to raise $289 million by selling 17 million shares at $17 each, after previously targeting up to $212.5 million. Goldman Sachs-affiliated entity will hold about 5.7%. It will list on Nasdaq as ATTO.
2 min readUS IPO Week Ahead: August IPO market opens with biotechs, a bank, and SpaceX earnings
The article previews four US IPOs scheduled for the coming week: Braveheart Bio (BRVE) raising $300M at a $1.4B market cap, Attovia Therapeutics (ATTO) raising $200M at $649M, River City Bank (RCBC) raising $136M at $703M, and Vogenx (VOGX) raising $75M at $173M. It also notes SpaceX (SPCX) earnings and a partial lock-up release that will expand tradable float.
6 min read